NEW YORK, NY / ACCESSWIRE / October 21, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Sarepta Therapeutics, Inc. (SRPT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sarepta-therapeutics-inc-loss-submission-form?prid=4006&wire=1
Lead Plaintiff Deadline: October 29, 2019
Class Period: September 6, 2017 to August 19, 2019
Allegations against SRPT include that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen's accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta's public statements were materially false and misleading at all relevant times.
Myriad Genetics, Inc. (MYGN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/myriad-genetics-inc-loss-submission-form?prid=4006&wire=1
Lead Plaintiff Deadline: November 26, 2019
Class Period: September 2, 2016 to August 13, 2019
Allegations against MYGN include that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
The Chemours Company (CC)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/the-chemours-company-loss-submission-form?prid=4006&wire=1
Lead Plaintiff Deadline: December 9, 2019
Class Period: February 16, 2017 to August 1, 2019
Allegations against CC include that: (1) Chemours had not appropriately accounted and accrued reserves for its environmental liabilities; (2) the possibility of costs exceeding accrued amounts was greater than the Company had represented to a point that could be material; (3) the Company's policies, standards and procedures were not properly designed to prevent unreasonable risk of harm to people and the environment (4) Chemours' handling, manufacture, use, and disposal of hazardous substances was not in accordance with applicable environmental laws and regulations; and (5) as a result of these misrepresentations, Chemours shares traded at artificially inflated prices.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: